Pharmaceutical Executive Europe - October 2008 - (Page EC14)
PharmaVision: Preferred partner in toll manufacturing Emerging from a management buyout from Aventis (now Sanofi Aventis), PharmaVision hit the Turkish market in 2002 as an exclusive contract manufacturer devoted to serving major multinational and local drugmakers and avoiding competition with its customers. It’s a vision that has served the Istanbul-based company well, drawing a pool of 14 clients and increasing its production volume by 100% during the last 5 years. “Our aim is to be a preferred manufacturer for the industry,” says Dr. Ünsal Hekiman, Company President of the Board and CEO. “We have a very strong quality assurance system.” Anticipating consistent growth for Turkish pharmaceutical sales and local production, Dr. Hekiman says he expects PharmaVision’s development to follow the market pace as it builds upon $50 million sales in 2007. Currently handling 9% of Turkey’s total pharma production — 1.3 billion packs industry-wide last year — the company aims to hit 10–12% of domestic volume. Dr. Hekiman says it’s a target that will be reached by improving upon cGMP standards and by continuing to invest in computer-automated production facilities. “As a toll manufacturing company we have to produce very economically,” he says. “We have to decrease our costs and we have to increase our efficiencies. 14 OCTOBER 2008 PHARMACEUTICAL EXECUTIVE EUROPE
http://www.embil.comhttp://www.embil.com
Table of Contents for the Digital Edition of Pharmaceutical Executive Europe - October 2008